

PHYSICIAN NEWSLETTER

VOL. 8, ISSUE 6 NOVEMBER 2022

Let's Do Well Together

In this issue:

- Important Event Dates
- Medical Staff Policy Updates
- Physician Recruitment

- Manatee Health at Home by Bayada
- Fentanyl Added to Drug Screen

Important Event Dates

LWRMC Annual Medical Staff Meeting

Thursday 11/10 6pm

@ Gold Coast Eagle Distributing

MCMS Holiday Social

Thursday 12/1 6-8pm

@ Dr. Aaron & Lori Sudbury's Home

Manatee Health at Home by Bayada

We are excited to announce the November 7th launch of Manatee Health at Home by BAYADA, a joint venture partnership between Manatee Healthcare System and BAYADA Home Health, that will further expand integrated care delivery network capabilities into patient homes.

Manatee Health at Home by BAYADA leverages the combined resources and expertise of UHS, Manatee Healthcare and BAYADA to strengthen the post-acute continuum of care to meet the increasing demand for in-home services, particularly among the aging population. It will help

patients of Manatee Healthcare and other providers to manage chronic conditions or recover from recent surgery, illness, or injury in the comfort and safety of their own homes. Manatee Healthcare comprises Manatee Memorial Hospital, Lakewood Ranch Medical Center. Lakewood Ranch Medical Group, Manatee Diagnostic Center and Manatee Physician Alliance.

Partnering for the Future of Care

Manatee Health at Home by BAYADA is:



A joint venture managed and run by BAYADA Home Health Care



The preferred home health care provider of Manatee Healthcare System



Now bringing the highest-quality health care at home to more people in West Central Florida

Together, we make it simple and easy for patients to get the coordinated care they need.





Medical Staff Policy Updates

REVISED:

- Drug Shortages
- Pharmacokinetic Consultation and Monitoring
- Sedation Titration and Monitoring Effects for Mechanically Ventilated Patients
- Stroke Alert Patient Care Management
- Targeted Temperature Management TTM

For questions or a copy of any Medical Staff Policy, contact Carla. Anzalone@lwrmc.com or call (941) 782-2182.

Fentanyl Added to Urine Drug Screen

Qualitative urine drug screen testing for Fentanyl became available in-house October 24th, 2022.

The ARK Fentanyl II Assay is an immunoassay intended for the qualitative detection of fentanyl in human urine. ARK Fentanyl II Assay provides a qualitative analytical test result. A more specific alternative chemical method must be used in order to obtain a confirmed positive analytical result. Gas Chromatography/Mass Spectrometry (GC/MS) or Liquid Chromatography/tandem Mass Spectrometry (LC-MS/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug test result, particularly when the test result is positive. Currently, this assay is sent to a reference laboratory for testing when requested. By testing the assay at LWRMC, results will available the same day testing occurs.

Order Information

- For the full urine drug screen panel: Drug Screen Urine
- For Fentanyl testing only: Fentanyl Urine

For questions, please contact Nicole Humenick, Laboratory Administrative Director 782-2332 or Nate Kolody, Core Laboratory Supervisor 782-2357.

Physician Recruitment

There are multiple outpatient Internal Medicine and Family Medicine physician opportunities available.

If you or a colleague are interested in a new opportunity, please contact Karen DeSimone at Karen.DeSimone@uhsinc.com or (941) 961-3107.